Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2011
Subject: Entry into a Material Definitive Agreement regarding the distribution of Fluviral Influenza Vaccine.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a contractual amendment.
Material Changes
The Company entered into an amendment to its Distribution Agreement with ID Biomedical Corporation of Quebec (IDB) concerning the Fluviral Influenza Vaccine. Key changes include:
- Extension of Termination Deadline: The deadline for IDB to provide written notice of termination for the 2012/2013 Flu Season was extended from October 1, 2011, to October 14, 2011.
- Negotiation Status: The parties had not completed negotiations for new terms by the original September 1, 2011 deadline.
- Automatic Termination: If IDB does not terminate the agreement by October 14, 2011, the Distribution Agreement will automatically terminate at the conclusion of the 2012/2013 Flu Season.
Outlook, Risks, and Contingencies
Contingency: The continuation of the distribution relationship for the 2012/2013 Flu Season is contingent upon IDB's decision to terminate or the parties reaching a new agreement by the extended deadline of October 14, 2011.
Risk: There is a risk that the Distribution Agreement will terminate automatically if no new agreement is signed and IDB does not exercise its termination right by the new deadline, potentially disrupting the supply of the vaccine product.
Investor Verification Checklist
- Verify whether ID Biomedical Corporation of Quebec issues a termination notice by October 14, 2011.
- Confirm if a new definitive agreement for the 2012/2013 Flu Season is executed before the automatic termination date.
- Assess the potential impact on revenue if the distribution of Fluviral Influenza Vaccine ceases after the 2012/2013 season.